TL;DR
This Phase 3 clinical trial, ICOGEN, investigated whether icotinib is non-inferior to gefitinib in treating advanced non-small-cell lung cancer (NSCLC) in patients who have already undergone chemotherapy. The study found that icotinib demonstrated comparable efficacy to gefitinib in terms of progression-free survival, while also showing a potentially better safety profile.
What Problem Does This Paper Address?
Lung cancer remains a leading cause of cancer-related death globally. For advanced non-small-cell lung cancer (NSCLC), chemotherapy has been a standard treatment. However, the advent of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has significantly improved outcomes, particularly in Asian populations where EGFR mutations are more prevalent. Gefitinib and erlotinib are established EGFR TKIs that have shown benefits over chemotherapy. Icotinib is another oral EGFR TKI that demonstrated promising antitumour activity and a favorable toxicity profile in earlier-phase trials. The critical question this paper addresses is whether icotinib can offer comparable efficacy to the established drug gefitinib in a head-to-head comparison, thereby providing a new therapeutic option for patients who have progressed on prior chemotherapy.
Methods
The ICOGEN trial was a randomized, double-blind, phase 3 non-inferiority study conducted across 27 sites in China. Patients aged 18-75 who had not responded to at least one platinum-based chemotherapy regimen were eligible. Participants were randomly assigned (1:1) to receive either icotinib (125 mg, three times daily) or gefitinib (250 mg, once daily) until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS), analyzed in the full analysis set. A non-inferiority margin of 1.14 for the hazard ratio (HR) of gefitinib versus icotinib was pre-defined, meaning non-inferiority would be established if the upper limit of the 95% confidence interval (CI) for the HR was below this value. Minimization methods were used for randomization, stratified by pathological type, smoking status, and ECOG performance status. All investigators, clinicians, and participants were masked to treatment allocation.
Datasets
Not discussed in the paper. The study involved patient recruitment and data collection from clinical trial participants.
Key Insights and Ideas
- Head-to-Head Comparison: This study represents the first prospective Phase 3 trial directly comparing two EGFR TKIs (icotinib vs. gefitinib) in pretreated NSCLC patients.
- Non-Inferiority Achieved: Icotinib successfully met its non-inferiority endpoint for progression-free survival compared to gefitinib, suggesting it's a viable alternative.
- Improved Safety Profile: Icotinib demonstrated a statistically significant reduction in overall treatment-related adverse events and, notably, drug-related diarrhea compared to gefitinib. This suggests a potentially better tolerability.
- EGFR Mutation Subgroup: While the overall study did not show significant differences in PFS between icotinib and gefitinib in patients with EGFR mutations, the data suggested a trend towards longer survival in the mutated subgroup for both drugs, reinforcing the importance of EGFR status.
- Non-Adenocarcinoma Benefit: A notable subgroup finding was that icotinib showed a significantly longer progression-free survival than gefitinib in patients without adenocarcinoma histology, although this was not statistically significant in the interaction analysis.
Key Results
- Progression-Free Survival (PFS): Icotinib was non-inferior to gefitinib. The hazard ratio (HR) for gefitinib versus icotinib was 0.84 (95% CI 0.67-1.05; p=0.13). Median PFS was 4.6 months for icotinib (95% CI 3.5-6.3) versus 3.4 months for gefitinib (95% CI 2.3-3.8).
- Overall Survival (OS): Overall survival was similar between the two groups. Median OS was 13.3 months for icotinib (95% CI 11.1-16.2) versus 13.9 months for gefitinib (95% CI 11.4-17.3).
- Objective Response Rate (ORR) and Disease Control Rate (DCR): Objective responses and disease control rates were comparable between the icotinib and gefitinib groups.
- Adverse Events: Patients receiving icotinib experienced fewer drug-related adverse events overall (61% vs. 70%; p=0.046) and specifically less drug-related diarrhea (19% vs. 28%; p=0.033) compared to gefitinib. No cases of interstitial lung disease were reported with icotinib.
Limitations and Future Work
- One-Sided Type I Error: The study used a one-sided type I error of 0.05 for the non-inferiority design. While the sample size was sufficient, this design choice is noted.
- EGFR Mutation Imbalance: The gefitinib group had a higher proportion of patients with mutated EGFR (59%) compared to the icotinib group (43%). The authors argue this imbalance did not distort findings, as EGFR mutations are generally associated with better TKI response.
- Subgroup Analysis for Non-Adenocarcinoma: The observed benefit of icotinib in patients without adenocarcinoma warrants further investigation in dedicated studies, especially considering the EGFR mutation status in this subgroup.
- Inconvenience of Dosing: The authors acknowledge that taking icotinib three times a day might be an inconvenience for patients compared to gefitinib's once-daily dosing.
Future work could focus on further exploring the benefits of icotinib in specific patient subgroups, particularly those without adenocarcinoma, and potentially investigating optimized dosing schedules.
Summary updated